Olr727 inhibitors are a class of chemical compounds that specifically target the Olr727 receptor, a member of the olfactory receptor family predominantly involved in the detection of specific chemical stimuli. These inhibitors are designed to interact with the Olr727 receptor, altering its normal function in the detection and transduction of olfactory signals. The precise mechanisms by which these inhibitors interact with the Olr727 receptor can vary, but typically involve binding to the receptor's active site or allosteric sites, thereby modulating its activity. This modulation can result in either competitive or non-competitive inhibition, depending on the specific binding interactions and structural characteristics of the inhibitor molecules. The study of Olr727 inhibitors provides significant insights into the structural and functional dynamics of olfactory receptors, contributing to a broader understanding of olfaction at the molecular level.
From a chemical perspective, Olr727 inhibitors can exhibit a diverse range of structures, often characterized by their ability to mimic or block natural ligands of the Olr727 receptor. These compounds can include small organic molecules, peptides, or larger macromolecular structures designed to achieve high specificity and affinity for the receptor. The development and characterization of these inhibitors involve sophisticated techniques such as high-throughput screening, molecular docking, and structure-activity relationship (SAR) studies. Additionally, advanced analytical methods, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to elucidate the binding interactions and conformational changes induced by these inhibitors. The ongoing research in this field not only enhances our understanding of olfactory receptor biology but also provides a foundation for exploring the broader implications of receptor-ligand interactions in sensory perception.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
EGFR inhibitor, potentially disrupting proteins in EGFR signaling pathways. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $90.00 | 1 | |
Aromatase inhibitor, potentially affecting estrogen production and related protein pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and RET tyrosine kinases, potentially affecting proteins in associated signaling pathways. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $85.00 $144.00 | 5 | |
Aromatase inhibitor, potentially affecting estrogen production and related protein pathways. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
CDK4/6 inhibitor, potentially impacting proteins involved in cell cycle regulation. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
BCR-ABL tyrosine kinase inhibitor, potentially disrupting proteins in leukemia signaling pathways. | ||||||
Exemestane | 107868-30-4 | sc-203045 sc-203045A | 25 mg 100 mg | $131.00 $403.00 | ||
Aromatase inhibitor, potentially affecting estrogen production and related protein pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
JAK1/2 inhibitor, potentially impacting proteins in JAK-STAT signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
RAF kinase inhibitor, potentially affecting proteins in RAF/MEK/ERK signaling pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Multi-kinase inhibitor, potentially affecting proteins in angiogenesis and cell proliferation pathways. | ||||||